CATX
AMEX · Biotechnology
Perspective Therapeutics Inc
$2.88
+0.00 (+0.00%)
Open$2.89
Previous Close$2.88
Day High$2.94
Day Low$2.77
52W High$6.16
52W Low$1.96
Volume—
Avg Volume1.47M
Market Cap320.77M
P/E Ratio—
EPS$-1.33
SectorBiotechnology
Analyst Ratings
Strong Buy
20 analysts
Price Target
+583.0% upside
Current
$2.88
$2.88
Target
$19.67
$19.67
$12.33
$19.67 avg
$23.14
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 1.37M | 2.18M | 70.28M |
| Net Income | -159,481,301 | -228,156,367 | -10,926,196 |
| Profit Margin | -11,665.3% | -11,082.0% | -15.6% |
| EBITDA | -170,599,674 | -257,621,507 | -18,107,687 |
| Free Cash Flow | — | — | -6,087,830 |
| Rev Growth | -37.1% | -37.1% | +8.8% |
| Debt/Equity | 0.01 | 0.01 | 0.76 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $265.21 | +0.28% | 74.0 | 466.74B |
| AMGN | Amgen Inc | $410.24 | +4.34% | 23.7 | 207.25B |
| GILD | Gilead Sciences Inc | $152.67 | +1.40% | — | 187.10B |
| VRTX | Vertex Pharmaceuticals Inc | $514.99 | +0.84% | 29.7 | 130.64B |
| REGN | Regeneron Pharmaceuticals | $803.90 | +0.72% | 18.6 | 80.58B |
| ALNY | Alnylam Pharmaceuticals Inc | $251.65 | +3.00% | 40.0 | 32.33B |